An Open Label, Multiple Ascending Dose Trial in Patients With T1DM to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin Tregopil and to Evaluate the Postprandial Glucose Control With Different Meal Types in Comparison With Insulin Aspart
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Insulin tregopil (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Biocon
- 03 Dec 2019 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 New trial record
- 06 Sep 2017 According to a Biocon media release, the company announced a partnership with Juvenile Diabetes Research Foundation (JDRF) to support a global multiple ascending dose study.